Showing 2,341 - 2,360 results of 23,583 for search '"T cells"', query time: 0.12s Refine Results
  1. 2341
  2. 2342

    Anti-IL-22 Antibody Attenuates Acute Graft-versus-Host Disease via Increasing Foxp3+ T Cell through Modulation of CD11b+ Cell Function by Jianbo Wu, Jian Gu, Shun Zhou, Hao Lu, Yunjie Lu, Ling Lu, Xuehao Wang

    Published 2018-01-01
    “…Transfer of splenocytes isolated from B6 mice into normal B6D2F1 mice induces acute graft-versus-host disease (aGVHD), resulting in the expansion of donor cytotoxic T lymphocytes that eliminate recipient B cells. The cytokine IL-22, secreted by Th1 cells, Th17 cells, and innate immune cells, is structurally related to IL-10. …”
    Get full text
    Article
  3. 2343
  4. 2344
  5. 2345

    The Relevance of CD117-Immunocytochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells by A. Sailasuta, D. Ketpun, P. Piyaviriyakul, S. Theerawatanasirikul, P. Theewasutrakul, A. Rungsipipat

    Published 2014-01-01
    “…Canine cutaneous mast cell tumors (MCT) are the lethal skin tumors. The biological behavior of the MCT cells is quite varied and unpredictable. …”
    Get full text
    Article
  6. 2346
  7. 2347

    Refining prognostic assessment of diffuse large B-cell lymphoma: insights from multi-omics and single-cell analysis unveil SRM as a key target for regulating immunotherapy by Xiaojie Liang, Jia Guo, Baiwei Luo, Weixiang Lu, Qiumin Chen, Yeling Deng, Yunong Yang, Liang Wang

    Published 2025-01-01
    “…Abstract Purposes Previous studies have demonstrated that proliferation, stroma or immunity strongly influence the prognosis and therapeutic resistance of diffuse large B-cell lymphoma (DLBCL). Herein, we aimed to integrate proliferation, stromal, and immune (PSI) features to systematically evaluate the risk stratification and explore novel therapeutic targets in DLBCL. …”
    Get full text
    Article
  8. 2348
  9. 2349
  10. 2350

    Circular RNA ITCH Is a Tumor Suppressor in Clear Cell Renal Cell Carcinoma Metastasis through miR-106b-5p/PDCD4 Axis by Ping Gao, Yong Huang, Yanmei Hou, Qian Li, Haimei Wang

    Published 2021-01-01
    “…High metastasis of clear cell renal cell carcinoma (ccRCC) significantly influenced survival rate of ccRCC patients. …”
    Get full text
    Article
  11. 2351

    Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma by Lucie Heinzerling, Michael Fluck, Caroline Robert, Celeste Lebbe, Erika Richtig, Sven D Koch, Ulrike Gnad-Vogt, Tobias Seibel, Thomas Eigentler, Juan Martin-Liberal, Sebastian Ochsenreither, Peter Mohr, Patrick Terheyden, Carsten Weishaupt, Michael Erdmann, Lukas Koch, Ainara Soria, Igor Samoylenko, Jürgen Krauß, Peter Brossart, Franz Georg Bauernfeind, Marina Gonzalez, Peter Wengenmayer, Ioannis Thomas, Artem Poltoratskiy, Marina Sekacheva, Beate Schmitt-Bormann, Gianluca Quintini, Martin Falk, Paula Codó, Arjun Oberoi, Jana Hess, Yulia Semiletova, Casilda Llacer Perez, Oliver Schönborn-Kellenberger

    Published 2025-02-01
    “…We investigated intratumoral (IT) administration of CV8102 in patients with anti-programmed cell death protein-1 (PD-1) therapy-naïve or anti-PD-1 therapy-refractory cutaneous melanoma (cMEL) and in patients with advanced cutaneous squamous cell carcinoma, head and neck squamous cell carcinoma and adenoid cystic carcinoma.Methods This open-label, cohort-based, phase I dose escalation study aimed to establish the maximum tolerated dose (MTD), recommended dose (RD), safety and preliminary efficacy of CV8102 as monotherapy or in combination with a PD-1 inhibitor. …”
    Get full text
    Article
  12. 2352
  13. 2353
  14. 2354
  15. 2355
  16. 2356
  17. 2357
  18. 2358
  19. 2359
  20. 2360